Global pharmaceutical firm XBiotech is planning to construct a 30,000-sf R&D laboratory in Austin, Texas. The facility will accelerate the creation of innovative treatments for infectious diseases. The project will be sited on the company's 48-acre headquarters campus, which includes a 33,000-sf research and manufacturing center that is also undergoing expansion to accommodate greater output, a larger workforce, increased inventory, and around-the-clock production operations.
XBiotech is currently developing the True Human™ antibody therapy for SARS-CoV-2, which utilizes antibodies from blood donors that have high natural immunity to the virus. The company has created an advanced screening platform that enables appropriate donors to be identified, and is working with South Texas Blood & Tissue Center to obtain materials for the True Human™ antibody discovery process.